Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma

Leukemia. 2019 May;33(5):1291-1296. doi: 10.1038/s41375-018-0374-8. Epub 2019 Jan 24.

Affiliations

¹ Department of Hematology and Medical Oncology, Emory University School of Medicine and the Winship Cancer Institute of Emory University, Atlanta, GA, USA.
² Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada.
³ Oncology Development, Abbvie, North Chicago, IL, USA.
⁴ Department of Hematology and Medical Oncology, Emory University School of Medicine and the Winship Cancer Institute of Emory University, Atlanta, GA, USA. lboise@emory.edu.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Apoptosis / drug effects
Apoptosis / genetics
Biological Assay / methods
Bridged Bicyclo Compounds, Heterocyclic / pharmacology
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
Drug Resistance, Neoplasm*
Humans
Multiple Myeloma / diagnosis
Multiple Myeloma / drug therapy*
Multiple Myeloma / etiology
Prognosis
Sulfonamides / pharmacology
Sulfonamides / therapeutic use*
Treatment Outcome
Tumor Cells, Cultured

Substances

Antineoplastic Agents
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
venetoclax

Grants and funding